about
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndromeCrystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors DesignPharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondTargeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosisThe Concise Guide to PHARMACOLOGY 2013/14: enzymes.Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: regulation of the PI3K activity.Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin.Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells.Targeting the Mammalian Target of Rapamycin in Lung Cancer.Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells.Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF.Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells.Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.
P2860
Q24608709-0B439C50-7D18-400A-82D8-A08EB073FA08Q27684223-DBFBCCCF-EA8D-4F78-9D08-B0DF45908737Q28080730-92BBCD98-AA4A-4051-8326-89CB90776798Q28397404-1BD24FEC-E8BA-4442-8CEB-5684743C5C23Q30486745-AA1A3E7C-B50D-4FDF-9A2C-59C6ED01795AQ35040191-B6502A97-A095-4416-B3D2-849D170291EDQ35542297-B1C91718-3ADC-400B-ACB7-B6CD02E5318CQ35702897-62A54C96-5591-4242-B01E-8180F6EAF89FQ36112720-3EA1B7D9-8353-4461-AE58-0417B29B0301Q36741115-77BDBC5B-1037-4D1F-9024-C8A59FBD8CA4Q37631210-DDE42477-9400-48A0-9F90-C87BE0D3F8ADQ37741531-824F6D61-D5EA-4B81-AC2C-543C48F85095Q42530564-71253AC5-6190-4961-9944-E854EFF73B3CQ42914388-4DFD0F37-DF54-4034-98C9-C98F0EFBA0FEQ51787318-ECD21B73-0B8F-424D-ABA2-CC1EEFC5A74BQ52644018-86F170E8-2623-4BE8-A92A-16FD7F757559
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
PI3K: a potential therapeutic target for cancer.
@en
PI3K: a potential therapeutic target for cancer.
@nl
type
label
PI3K: a potential therapeutic target for cancer.
@en
PI3K: a potential therapeutic target for cancer.
@nl
prefLabel
PI3K: a potential therapeutic target for cancer.
@en
PI3K: a potential therapeutic target for cancer.
@nl
P2093
P2860
P356
P1476
PI3K: a potential therapeutic target for cancer.
@en
P2093
Bao-Can Wang
Yingwei Chen
Yongtao Xiao
P2860
P304
P356
10.1002/JCP.23038
P577
2012-07-01T00:00:00Z